Triumphal Biopharma and BioNTech (BNTX.US) have agreed to a more than $1.2 billion collaboration to develop 3D-printed oral RNA medicines.
On July 24, Triastek announced that it has entered into a potential $1.2 billion research collaboration and platform technology licensing agreement with BioNTech (BNTX.US). Under the agreement, the two companies will develop oral RNA therapeutics based on 3D printing technology to meet unmet medical needs.
Under the agreement, Triastek will contribute its expertise in innovative oral tablet design, which is achieved through 3D printing technology, to optimize the delivery of RNA therapeutics in the gastrointestinal mucosa, minimize degradation in the gastrointestinal tract and deliver RNA therapeutics to the highest absorption rate in the gastrointestinal tract. Triastek has the capability to create unique external and internal geometric shapes in tablet structures, including multi-layer and multi-chamber designs, to optimize the delivery of novel RNA therapeutics.
Under the agreement terms, Triastek will receive a $10 million upfront payment and is eligible to receive up to $1.2 billion in development, regulatory and commercial milestone payments.